Natural Products from Marine Fungi for the treatment of cancer


 

The MarineFungi consortium demonstrated the sustainable exploitation of marine natural resources providing appropriate culture conditions. New anti cancer compounds are now  characterised to the stage of in vivo proof of concept ready to enter further drug development.

We developed the technological basis for a sustainable use of marine microbial products along the added-value chain from the marine habitat to the drug candidate and process concept.

Results from the Marine Fungi projects were presented at a dedicated scientific track at ELRIG - Research and Innovation Impact into Cancer

11. March 2014

The full program is available here: program

 

Presentations

Johannes Imhoff, GEOMAR - Marine Fungi: Strategy and General Overview    

Antje Labes, GEOMAR - Marine Fungi: Understanding the Biology of Marine Fungi for Produktion of Secondary Metabolites to Establish a Natural Produkt Library
   
Russell Cox,  Leibniz  University of Hannover - Understanding Fungal Biosynthetic Gene Clusters (available soon)
       
Phil Gribbon, European Screening Port: Marine Fungi - a  Phenotypic Assay Approach to Identifying Anti-­cancer Compounds
       
Eriko Takano, University of Manchester Biotechnology 2.0: Use of Synthetic Biology for Natural  Products (available soon)
       
Isabel Coma, GlaxoSmithKline: Mining Natural Products Screening Data for Target Class Chemical Motifs (available soon)
      
Esther Schmitt, Novartis Pharma AG: Innovation and Tradition in Industrial Natural Products Research

Lutz Müller-­Kuhrt,  Analyticon Discovery Novel Strategies for Natural Product Based Macrocyclic Libraries (available soon)  

Rebecca Goss, University of St. Andrews: Elucidating and Exploiting Biosynthesis (available soon)
  
Stephen Wrigley, Hypha Discovery Ltd: Marine Fungi - Charting the Chemistry of Hits from an Anticancer Screening Campaign   

Poster

A. Kramer/ H.C. Beck/ A. Kumar: Quantitative proteomics of the regulation patterns in scopularide A and B production by a marine Scopulariopsis brevicaulis strain LF580

A. Tamminen/ M. Wiebe:  Production of bioactive compound(s) with the marine fungus Calcarisporium sp Production of bioactive compound(s) with the marine fungus Calcarisporium sp

A. Tamminen/ M. Wiebe: Scopularide A production from the Marine Fungus Scopulariopsis brevicaulis

B. Ellinger et al.: A phenotypic screening approach to identify anti-cancer compounds derived from marine fungi

B. Kebede et al.: Establishing the Secondary Metabolite Profile of a Marine Fungus: Tolypocladium geodes MF458

J. Silber et al.: Bioactive metabolites of a marine Calcarisporium sp.

A Kumar & F Kempken: Genome sequencing, assembly and annotation of a marine fungal isolate of Scopulariopsis brevicaulis using three different next generation sequencing technologies

A Kumar & F Kempken: Next-generation genome and transcriptome based methods for the exploration of secondary metabolites from marine fungi for the treatment of cancer

K.S. Pedersen et al. : Phosphorylation dynamics in response to a novel anticancer compound from marine fungi

J. Landskron & K. Tjasken: Natural Products from Marine Fungi for the treatment of cancer

A. Stokka et al.: An EU-OPENSCREEN partner: The Chemical Biology Platform in Oslo

Follow us on

 

newsticker

reporting is now under way

Our End User Conference was the last public presentation of our consortium as a whole with all our findings and our outlook. Now everybody is busy with last experiments and the reporting.

ELRIG Poster prize

Congratulations to Bernhard Ellinger - his poster "A phenotypic screening approach to identify anti-cancer compounds derived from marine fungi" won the ELRIG 2014 poster prize.

ELRIG Conference

Our innovation zone booth at the ELRIG conference and exhibition at Telford

Showing 1 - 3 of 72 results.
Items per Page 3
of 24